Abstract 1285
Background
Anaphylatoxin C5a is released in the cancer microenvironment and binds to the C5aR receptor, which in turns promotes protumoral inflammation and immune suppression through recruitment and activation of myeloid derived suppressor cells (MDSC) and neutrophils. Overexpression of C5aR has been reported in several tumor types and correlates with aggressive tumor features and poor prognosis. Additionally, C5aR was found to be upregulated in NSCLC patients in progression after an initial response to an anti-PD-(L)1 therapy (aPD1). IPH5401, a fully human anti-C5aR1 antibody, inhibits the C5a mediated effects on MDSC and neutrophils. Preclinical data suggest that the combined blockade of C5aR1 and aPD1 synergistically reduce tumor growth and delay tumor progression. These data suggest that combining IPH5401 with aPD1 may improve efficacy and overcome secondary resistance to aPD1.
Methods
This is an ongoing phase I to evaluate the safety of IPH5401 + durvalumab (durva) in advanced solid tumors. In the 3 + 3 dose-escalation, patients (pts) receive IPH5401 at 4 dose levels (DL) (DL1, DL2, DL3 [Q1w] and DL4 [Q2w]) single agent during the first 2 weeks (w) then in combination with durva 1500 mg Q4w. Blood samples are collected at various time points for characterization of pharmacokinetics, pharmacodynamics and immunogenicity. Upon completion of the phase I part and determination of a recommended phase II dose, expansion cohorts in NSCLC and HCC will be activated.
Results
As of April, 30th 2019, 12 pts have been enrolled (4 HCC, 2 UCC, 5 NSCLC, 1 RCC). No DLT was seen to date. DL3 and DL4 are ongoing. A total of 11 treatment related AEs (TRAEs) were reported in 5 patients: G2 diarrhea with lymphocytic colitis (n = 1), G1 diarrhea (n = 1), G1 skin rashes (n = 2), G1 White blood cell decrease (n = 1), G1 pneumopathy (n = 1), G1 lung disorder (n = 1), G1 fatigue (n = 1), G1 arthralgia (n = 1), G1 back pain (n = 1), G1 musculoskeletal chest pain (n = 1). There were no grade 3/4 TRAEs and no TRAEs that led to study discontinuation.
Conclusions
Preliminary results of this combination of IPH5401 plus durva suggest a manageable toxicity profile. Results of dose escalation including PK/PD data will be presented.
Clinical trial identification
NCT03665129.
Editorial acknowledgement
Legal entity responsible for the study
Innate Pharma.
Funding
Innate Pharma and AstraZeneca.
Disclosure
C. Massard: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self), Advisory / Consultancy: Astellas; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Bayer; Honoraria (self), Advisory / Consultancy: Beigene; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Advisory / Consultancy: Debiopharm; Honoraria (self), Advisory / Consultancy: Genentech; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: MSD; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Sanofi; Honoraria (self), Advisory / Consultancy: Orion. P. Cassier: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche/Genentech; Honoraria (self), Research grant / Funding (institution): Blueprint Medicines; Honoraria (self), Travel / Accommodation / Expenses: Amgen; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Celgene; Research grant / Funding (institution): Plexxikon; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Research grant / Funding (institution): Taiho; Research grant / Funding (institution): Toray; Research grant / Funding (institution): Transgene; Research grant / Funding (institution): Loxo; Research grant / Funding (institution): GSK; Research grant / Funding (institution): Innate Pharma; Research grant / Funding (institution): Janssen. J.C. Bendell: Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Gilead; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Genentech/Roche; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Research grant / Funding (institution): Five Prime; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Lilly; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Merck; Research grant / Funding (institution), Travel / Accommodation / Expenses: MedImmune; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Celgene; Advisory / Consultancy, Research grant / Funding (institution): EMD Serono; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Taiho; Advisory / Consultancy, Research grant / Funding (institution): MacroGenics; Advisory / Consultancy, Research grant / Funding (institution): GSK; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Novartis; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: OncoMed; Advisory / Consultancy, Research grant / Funding (institution): LEAP; Research grant / Funding (institution): TG Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Innate Pharma; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: BI; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo. D.B. Marie: Shareholder / Stockholder / Stock options, Full / Part-time employment: Innate Pharma. M. Blery: Shareholder / Stockholder / Stock options, Full / Part-time employment: Innate Pharma. C. Morehouse: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. M. Ascierto: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. R. Zerbib: Shareholder / Stockholder / Stock options, Full / Part-time employment: Innate Pharma. E. Mitry: Shareholder / Stockholder / Stock options, Full / Part-time employment: Innate Pharma. A.W. Tolcher: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AbbVie; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: ADC Therapeutics; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Adagene; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Agenus; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: AroBioTX; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ascentage; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Aximmune; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Bayer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: BioInvent; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Birdie; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Boston Bio; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: EMD Serono; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Forbius; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: HBM partners; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Ignitia; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Immunome; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Immunomet; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Jazz; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Mekanistic; Research grant / Funding (institution): Innate Pharma.
Resources from the same session
5579 - Quality of informed consent in clinical trials patients
Presenter: Gianluca Catania
Session: Poster Display session 3
Resources:
Abstract
5147 - Patient's rights: Where do we stand?
Presenter: Maja Kozuh
Session: Poster Display session 3
Resources:
Abstract
1279 - The oncology nurse coordinator’s role in a digestive oncology department: Impact on patient and hospital
Presenter: Fouad Awada
Session: Poster Display session 3
Resources:
Abstract
1670 - Nursing model for a breast cancer unit at the Catalan Institute of Oncology
Presenter: Ana Rodriguez-ortega
Session: Poster Display session 3
Resources:
Abstract
3936 - Role of cancer nurse in the prevention and control of acute deterioration for oncohematologic patient
Presenter: Raquel Azor Portolés
Session: Poster Display session 3
Resources:
Abstract
2789 - Standardized nursing care in the department of radiotherapy of a network of cancer centres
Presenter: José Delgado
Session: Poster Display session 3
Resources:
Abstract
4482 - Exploring anxiety, depression and quality of life of ambulatory cancer patients during chemotherapy.
Presenter: Theodoula Adamakidou
Session: Poster Display session 3
Resources:
Abstract
3075 - Implementing a Cancer Survivorship Program for Individuals with Recurrent Breast Cancer
Presenter: Darcy Burbage
Session: Poster Display session 3
Resources:
Abstract
3869 - The perceptions of parents/guardians regarding their child/adolescent’s experience of reflexology or non-specific foot massage The perceptions of parents/guardians regarding their child/adolescents experience of reflexology or non-specific foot massage
Presenter: Patricia Fox
Session: Poster Display session 3
Resources:
Abstract
4064 - Quality of life in survivors of adult haematological malignancies
Presenter: Anita Immanuel
Session: Poster Display session 3
Resources:
Abstract